.svg){kind=small}
Advances in Cardiovascular Science: From Discovery to Translation
Dr. Jörg Taubel, CEO of Richmond Pharmacology, will be attending the Basic Cardiovascular Sciences (BCVS) Scientific Sessions 2024,held from 22nd to 25th July in Chicago, Illinois.
This event features cutting-edge research and advancements in cardiovascular science, including topics like cardiac gene and cell therapy, tissue engineering, and cardiac metabolism.
Attendees will include basic cardiovascular scientists, molecular and cellular biologists, translational investigators, clinical trialists, and practicing cardiologists.
To connect with Dr. Taubel during the event, please reach out to arrange a meeting.
To find out more, click here.
-min.jpg)
.jpg)
Latest news
Richmond Appoints Lisa Campbell as Director of Regulatory Strategy
April 23, 2025
Richmond Pharmacology is pleased to announce the appointment of Lisa Campbell as Director of Regulatory Strategy
Read moreVon Willebrand Disease – First Stage of Hemab Therapeutics’ Trial Completed and New Patients Invited to Enrol
April 2, 2025
Richmond has completed dosing the first cohort of patients in Velora Pioneer, a phase 1/2 clinical trial investigating Hemab...
Read moreEvents
Swiss Biotech Day 2025
5–6 May 2025
Richmond Pharmacology is pleased to confirm our participation at Swiss Biotech Day 2025
View event
